US and UK Conclude Duty-Free Pact on Pharmaceuticals.
Britain and America have secured a significant bilateral deal that will keep no tariffs on British drug products entering the US market.
Agreement Details of the Pact
As part of the deal, the UK has pledged to increase spending on medicines through the public health system. This commitment secures that duties on these vital goods will be held at nothing for a duration of 36 months.
This agreement comes after recent statements to hike import taxes on patented drug imports, with figures floated up to one hundred percent.
"This deal with the United Kingdom strengthens the global environment for cutting-edge drugs and establishes long-overdue balance to American-British medicine commerce," an announcement said.
Commercial Significance
Medicines constitute one of the Britain's biggest exports to the United States, which is clearly the primary market for major UK drugmakers.
Export figures indicate that in the 12 months leading up to last September, the UK sold medicines totaling £11.1bn to the US. This value accounted for nearly one-fifth of all goods exports in that timeframe.
"This guarantee secures employment, increases capital expenditure and paves the way for the UK to establish itself as a worldwide center for medical research," a minister stated.
Key British Pledges
The agreement includes several key changes from the United Kingdom:
- Higher Cost Ceiling: The UK will lift the affordability limit at which it deems new therapies to be unaffordable by 25%.
- Higher Drug Budget: There is a aim to increase overall NHS spending on medicines from 0.3 percent of GDP to 0.6% over the following ten-year period.
- Refund Ceiling: The percentage pharmaceutical firms must pay back to the NHS to stay within budget will be capped at 15%. In the past, rebates were more than twenty percent.
Industry Background
This agreement comes amid a long-running dispute between the pharmaceutical industry and the UK government over drug pricing and approval rates.
This friction were heightened by claims that US consumers were charged a premium for the identical medicines than patients in the other developed nations.
Over the last 18 months, several major pharmaceutical investments in the UK have been delayed or scrapped, while substantial expansions have been pledged toward projects in the United States.
A senior figure acknowledged that the NHS must increase expenditure on medicines, noting that its expenditure on drugs had shrunk as a proportion of its total funding over the previous ten-year period.
